Last reviewed · How we verify
KM257 Bispecific antibody
KM257 Bispecific antibody is a Biologic drug developed by Xuanzhu Biopharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | KM257 Bispecific antibody |
|---|---|
| Sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KM257 Bispecific antibody CI brief — competitive landscape report
- KM257 Bispecific antibody updates RSS · CI watch RSS
- Xuanzhu Biopharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about KM257 Bispecific antibody
What is KM257 Bispecific antibody?
KM257 Bispecific antibody is a Biologic drug developed by Xuanzhu Biopharmaceutical Co., Ltd..
Who makes KM257 Bispecific antibody?
KM257 Bispecific antibody is developed by Xuanzhu Biopharmaceutical Co., Ltd. (see full Xuanzhu Biopharmaceutical Co., Ltd. pipeline at /company/xuanzhu-biopharmaceutical-co-ltd).
What development phase is KM257 Bispecific antibody in?
KM257 Bispecific antibody is in Phase 1.